ArticleRheumatology (Oxford, England)2025

Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis.

Xavier Sendaydiego et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.